Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 5501-5507 |
| Seitenumfang | 7 |
| Fachzeitschrift | Journal of the American Chemical Society |
| Jahrgang | 136 |
| Ausgabenummer | 14 |
| Publikationsstatus | Veröffentlicht - 9 Apr. 2014 |
| Extern publiziert | Ja |
Abstract
Mupirocin, a clinically important antibiotic produced via a trans-AT Type I polyketide synthase (PKS) in Pseudomonas fluorescens, consists of a mixture of mainly pseudomonic acids A, B, and C. Detailed metabolic profiling of mutant strains produced by systematic inactivation of PKS and tailoring genes, along with re-feeding of isolated metabolites to mutant stains, has allowed the isolation of a large number of novel metabolites, identification of the 10,11-epoxidase, and full characterization of the mupirocin biosynthetic pathway, which proceeds via major (10,11-epoxide) and minor (10,11-alkene) parallel pathways.
ASJC Scopus Sachgebiete
- Chemische Verfahrenstechnik (insg.)
- Katalyse
- Chemie (insg.)
- Allgemeine Chemie
- Biochemie, Genetik und Molekularbiologie (insg.)
- Biochemie
- Chemische Verfahrenstechnik (insg.)
- Kolloid- und Oberflächenchemie
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Journal of the American Chemical Society, Jahrgang 136, Nr. 14, 09.04.2014, S. 5501-5507.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Biosynthesis of mupirocin by pseudomonas fluorescens NCIMB 10586 involves parallel pathways
AU - Gao, Shu Shan
AU - Hothersall, Joanne
AU - Wu, Ji'En
AU - Murphy, Annabel C.
AU - Song, Zhongshu
AU - Stephens, Elton R.
AU - Thomas, Christopher M.
AU - Crump, Matthew P.
AU - Cox, Russell J.
AU - Simpson, Thomas J.
AU - Willis, Christine L.
PY - 2014/4/9
Y1 - 2014/4/9
N2 - Mupirocin, a clinically important antibiotic produced via a trans-AT Type I polyketide synthase (PKS) in Pseudomonas fluorescens, consists of a mixture of mainly pseudomonic acids A, B, and C. Detailed metabolic profiling of mutant strains produced by systematic inactivation of PKS and tailoring genes, along with re-feeding of isolated metabolites to mutant stains, has allowed the isolation of a large number of novel metabolites, identification of the 10,11-epoxidase, and full characterization of the mupirocin biosynthetic pathway, which proceeds via major (10,11-epoxide) and minor (10,11-alkene) parallel pathways.
AB - Mupirocin, a clinically important antibiotic produced via a trans-AT Type I polyketide synthase (PKS) in Pseudomonas fluorescens, consists of a mixture of mainly pseudomonic acids A, B, and C. Detailed metabolic profiling of mutant strains produced by systematic inactivation of PKS and tailoring genes, along with re-feeding of isolated metabolites to mutant stains, has allowed the isolation of a large number of novel metabolites, identification of the 10,11-epoxidase, and full characterization of the mupirocin biosynthetic pathway, which proceeds via major (10,11-epoxide) and minor (10,11-alkene) parallel pathways.
UR - http://www.scopus.com/inward/record.url?scp=84897981244&partnerID=8YFLogxK
U2 - 10.1021/ja501731p
DO - 10.1021/ja501731p
M3 - Article
C2 - 24625190
AN - SCOPUS:84897981244
VL - 136
SP - 5501
EP - 5507
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
SN - 0002-7863
IS - 14
ER -